Skip to content

Research Support

Training + Education

Clinical Research Seminar Series

Every other month, we hold Q+A sessions about issues that matter to investigators. These interactive sessions can tell you about new developments in research, and we set aside most of our time for questions and discussion. Sign up for our partner network to find out when the next session is. 

AHS and the University of Alberta offer a series of training courses. We can direct you to these courses as needed. 

Weiser Course

As of July 15, 2009, all newly hired research study coordinators are required to take the Weiser course. This two-day intensive training program will enhance your skills and knowledge of clinical trial research. The course offers practical, hands-on workshops and presentations for coordinators at all levels in all settings and areas of care.

View Course Details

GCP + SOCRA

From time to time, we offer the Good Clinical Practice (GCP), a required international science and ethics standard for designing, running, recording, and reporting trials with human participants. We also support the Society of Clinical Research Associates’ (SOCRA) International Certification Program, which recognizes investigators as Certified Clinical Research Professionals (CCRPs).

AHS Laboratory Services

Here you’ll find forms and documents needed to obtain quotes for services from the AHS research lab, to apply for AHS research lab operational approval, and AHS lab regulatory documents for FDA and Health Canada Audits.

AHS Laboratory Services

Clinical Investigation Unit

Opened in 2005, NACTRC’s Phase 1 unit is the only Phase 1 unit in Canada that’s located within a major tertiary care facility: the University Hospital. The 3,300-square-foot, eight-bed ward is designed to assess drug safety, pharmacokinetics, pharmacodynamics, and tolerability in a controlled environment. You can conduct Phase 1–4 studies on your own or use our staff with their full range of clinical investigations experience.

Learn More

Trial + Study Startup

Risk Group II Human Biosafety

More and more, studies are using genetically modified organisms as vectors or therapeutic agents in research studies. This growing area of research has resulted in a response by government and regulatory groups to potential safety concerns.

We formed the Risk Group II Biological Safety Committee (RGII BSC). This government-defined term includes genetically modified organisms that may be harmful to humans, the environment, and their biological products. This includes human tissues, cells, blood, fluids, and native, modified, or purified proteins. The term “infectious” includes viral vectors, organisms, or genetic systems that could replicate themselves and harm humans or the environment.

The RGII BSC is supported by biological safety officers from the University and AHS, as well as an expert in human gene transfer. The committee works with investigators, research coordinators, and sponsors to ensure the proper level of safety controls are being used. They can also provide in-house training if sponsor training isn’t sufficient.

Investigator-Initiated Research

Our team of in-house and contract experts can help you design research study protocols and biometric analysis for a Health Canada clinical trial application (CTA). In the process, we’ll connect you with the University’s Quality Management in Clinical Research Office (QMCR) to make sure your study is properly reviewed. This department oversees human research at the University and will post your CTA to ClinicalTrials.gov.

There are also a number of groups associated with the University and AHS who can help support research studies in Alberta. These include WCHRI, EPICOR, SPOR, and AHS Research Facilitation.

Have questions? Contact us.